Eric Zinszer
About Eric Zinszer
Company
Eric Zinszer is currently employed by Bristol Myers Squibb. He holds the role of Senior Manager Regional Lead and has been working in this capacity since December 2019. The position involves comprehensive management responsibilities in a remote setting.
Title
Eric Zinszer serves as the Senior Manager Regional Lead at Bristol Myers Squibb. His role encompasses significant oversight and leadership within the company’s regional operations, leveraging his extensive background in pharmaceutical development and quality management.
Previous Roles at AstraZeneca
Eric Zinszer previously worked at AstraZeneca for a combined duration of 19 years. From 2018 to 2019, he was the Lead Quality Advisor/Lead Auditor in the Raleigh-Durham, North Carolina area. Before that, he served as Lead Quality Assurance Advisor from 2000 to 2018 in Gaithersburg, Maryland. His roles at AstraZeneca involved extensive quality assurance responsibilities and auditing tasks, contributing significantly to the company's compliance and quality control processes.
Experience at Catalent Pharma Solutions
In 2019, Eric Zinszer briefly held the position of Quality Manager at Catalent Pharma Solutions in Durham, North Carolina. His tenure lasted for three months, during which he contributed to quality management practices within the organization.
Education and Certifications
Eric Zinszer achieved a BA in Biological Sciences from the University of Delaware, studying there from 1987 to 1992. He later earned a Certificate, Green Belt from Villanova University in 2010, which signifies his training in process improvement methodologies.
Past Laboratory Experience
From 1993 to 1999, Eric Zinszer worked as a Lab Tech at SDIX LLC - An OriGene Company. This role provided him with foundational laboratory experience, which has been integral to his career in quality assurance and pharmaceutical development.
Problem Solving and Conflict Management
Eric Zinszer is particularly skilled in problem solving and conflict management. His ability to address and resolve issues effectively has been a significant asset throughout his more than 23 years of experience in pharmaceutical development.